NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/09/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,794.93 mln
Float83.07 mln
Earnings Date11/10/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
26.37
Highly suspicious
1-Year Forecast
52.15
Strong upside
Relative Strength
14
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
Pre-Tax Margin
-75%
Severely loss-making
Business Description
IDEAYA Biosciences is a cancer drug company based in South San Francisco that focuses on matching treatments to patients based on their specific genetic profile. The company is developing a broad pipeline of targeted therapies across multiple clinical trials, addressing cancers driven by distinct molecular mutations, including uveal melanoma, small cell lung cancer, and breast, prostate, and colorectal cancers, among others. IDEAYA also uses advanced machine-learning tools and genetic screening technology to identify new drug targets and support its discovery efforts. The company works alongside major partners including GlaxoSmithKline, Pfizer, Gilead Sciences, and Novartis, and has been operating since 2015.
